

VERTEX PHARMACEUTICAL

ISIN: US92532F1003 WKN: 92532F100 Asset Class: **Stock**


Company

2021/03/05 22:00:00



Price
211.98
USD

Difference ▲ 2.02%(4.19)



Contact Details

VERTEX PHARMACEUTICALS, INC.

Tel: 1-617-341-6100

--

Fax: -

50 Northern Avenue

Web: <http://www.vrtx.com>

02210 Boston

E-mail:

mediainfo@vrtx.com

Company Profile

Vertex Pharmaceuticals, Inc. is a global biotechnology company. It engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2020		2019		2018	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	8,133,379,000		4,822,829,000		3,843,109,000	
Common stock capital		2,599,000		2,589,000		2,546,000
Fixed assets	3,618,429,000		3,495,636,000		2,402,789,000	
Equity capital of a company		8,686,815,000		6,085,244,000		4,435,203,000
Cash and cash equivalents	5,988,845,000		3,117,326,000		2,650,134,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		1,877,533,000		1,334,827,000		1,120,292,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		1,187,460,000		898,394,000		690,403,000
Different income		-		-		-
Other liabilities		297,955,000		275,526,000		108,853,000
Total assets	11,751,808,000	11,751,808,000	8,318,465,000	8,318,465,000	6,245,898,000	6,245,898,000

Balance notes

	2020	2019	2018
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	3,400	3,000	2,500
Equity ratio	73.92%	73.15%	71.01%
Debt-equity ratio	35.28%	36.70%	40.83%

Others

	2020	2019	2018
Tax Expense Rate	13.00%	15.64%	-247.71%

VERTEX PHARMACEUTICAL

ISIN: US92532F1003 WKN: 92532F100 Asset Class: Stock

Income statement

	2020	2019	2018
Turnover	6,209,397,000	4,130,275,000	3,048,849,000
Net income	2,711,647,000	1,176,810,000	2,096,395,000
EBIT	2,608,867,525	1,150,012,333	524,932,900
Operating income before taxes	3,116,798,000	1,394,919,000	600,241,000
Cash Flow	3,253,505,000	1,569,330,000	1,270,286,000
Net interest income	-35,912,000	5,176,000	-34,119,000
Research and development expenses	1,829,537,000	1,754,540,000	1,416,476,000
Income taxes	405,151,000	218,109,000	-1,486,862,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	1,511,258	1,139,268	1,009,169

Board of Directors

Members of Management Board

Jeffrey Leiden	Chairman of Board of Directors
Alan Garber	Member of Board of Directors
Sangeeta Bhatia	Member of Board of Directors
Bruce Sachs	Member of Board of Directors
Diana McKenzie	Member of Board of Directors
Lloyd Carney	Member of Board of Directors
Margaret McGlynn	Member of Board of Directors
Terrence Kearney	Member of Board of Directors
Yuchun Lee	Member of Board of Directors
Reshma Kewalramani	Chairman of Managing Board
Bastiano Sanna	Member of Executive Committee
Carmen Bozic	Member of Executive Committee
David Altshuler	Member of Executive Committee
Nia Tatsis	Member of Executive Committee
Amit Sachdev	Member of Executive Committee
Charles Wagner	Member of Executive Committee
Damian Wilmot	Member of Executive Committee
Ludovic Fenaux	Member of Executive Committee
Michael Parini	Member of Executive Committee
Michael Partridge	Member of Executive Committee